The Long-Term Treatment of Hypertension with Thiazide Diuretics D

Total Page:16

File Type:pdf, Size:1020Kb

The Long-Term Treatment of Hypertension with Thiazide Diuretics D Postgraduate Medical Journal (October 1971) 47, 639-643. Postgrad Med J: first published as 10.1136/pgmj.47.552.639 on 1 October 1971. Downloaded from The long-term treatment of hypertension with thiazide diuretics D. G. BEEVERS M. HAMILTON M.B., M.R.C.P. M.D., F.R.C.P. Medical Registrar Physician J. E. HARPUR M.B., B.S Research Registrar Chelmsford Group ofHospitals Summary TABLE 1. Aetiology of hypertension Two hundred and twenty-seven cases of moderate to Essential hypertension 198 severe hypertension were treated with thiazide Chronic pyelonephritis 23 diuretics alone for periods of up to 12 years. In 80%. Polycystic kidneys 2 the Disseminated lupus 1 hypertension was adequately controlled without Parathyroid adenoma 1 additional antihypertensive agents. Renal artery stenosis 2 Hypokalaemic alkalosis was common despite Total 227 potassium supplements-but caused no symptoms. The incidence of diabetes and gout was low. TABLE 2. Mode of presentation Protected by copyright. It is concluded that thiazide diuretics provide Headache 70 excellent control of hypertension with very few side Routine medical examination 40 effects. Breathlessness 38 Dizziness 20 Introduction Angina pectoris 17 Pregnancy 19 Thiazide diuretics have been used in the treatment Strokes 12 of hypertension since the introduction of chloro- Coronary thrombosis 8 thiazide in 1957. The mode of action is obscure, but Grade III retinopathy 19 is probably unrelated to the natriuretic effect Grade IV retinopathy 3 Left ventricular enlargement 67 (Maronde, Milgrom & Dickey, 1969; Dollery et aL, Cardiac failure 1962) and may 33 be due to relaxation of arteriolar Blood urea at beginning of study: smooth muscle. Whilst thiazides have few clinically 40-60 mg/100 ml 33 evident side-effects, it is commonly held that hypo- Over 60 mg/100 ml 1 kalaemic alkalosis, carbohydrate intolerance and hyperuricaemia are frequent unwanted effects. The of those presenting in the accelerated phase is http://pmj.bmj.com/ thiazides are most frequently used as an adjunct to naturally low as such patients usually require more potent antihypertensive drugs. immediate and more potent therapy (Hamilton, 1966). Patients and methods Patients were generally treated on an out-patient Two hundred and twenty-seven patients with basis and seen within 6-weekly intervals until moderate to severe hypertension (eighty-nine males, adequate blood pressure control was achieved, average age 52 6, 138 females, average age 52-3) thereafter they were seen at 4-6-monthly intervals. on October 2, 2021 by guest. were treated with a thiazide diuretic alone-usually All underwent routine clinical examination, their hydroflumethiazide-and followed for periods of up urine was tested and they had regular checks of their to 12 years. This number does not include those blood urea and electrolytes. Ninety-six cases had hypertensives who required additional antihyper- their serum uric acid checked on several occasions. tensive agents within a few months of starting The duration of follow-up is shown in Fig. 1. thiazide therapy. The patients underwent conven- Eleven cases were referred to us whilst on other tional investigations in order to determine the anti-hypertensive agents which had failed to control aetiology of their hypertension (Table 1). their hypertension. In these cases an untreated blood The mode of presentation and complications at pressure level was not available. presentation (Table 2) were the same as commonly The majority (71%Y) of patients were treated with found in any group of hypertensives, the proportion 200 mg of hydroflumethiazide (Hydrenox, Boots). J. E. 640 D. G. Beevers, M. Hamilton and Harpur Postgrad Med J: first published as 10.1136/pgmj.47.552.639 on 1 October 1971. Downloaded from 20 0 0-11 12-2324-35 36-4748-59 60-71 72-8384-9596-107108-120 120+ Months FIG. 1. Duration of treatment with thiazides alone (227 patients). The remainder received smaller doses, and a few had TABLE 3. Thiazides in hypertension other thiazide diuretics in equivalent doses. Potas- Standard 95°/ sium supplements were recommended as a routine- Mean error confidence usually slow K (Ciba) in a dose of 1-2 tablets daily BP of mean interval (for (600-1200 g daily), but 22%Y were given increasing (SEM) mean BP) doses if their serum potassium fell to very low Pre-treatment levels. In eight cases the thiazide was given on 5 days Systolic 203 4 1-8 199 9-206 9 in 7 in an attempt to lessen the hypokalaemic effect. Diastolic 120-6 1-0 118-7-1225 Protected by copyright. On thiazides Systolic 161-6 1-3 1590-164-2 Results Diastolic 96-8 07 954- 98-2 Bloodpressure control The mean and standard error, and 95°/ confidence interval for the mean blood pressure before and Complications ofhypertension when receiving treatment are shown in Fig. 2 and Those patients in whom the blood pressure Table 3. Good control (diastolic blood pressure less became uncontrolled were given additional anti- than 100 mmHg) was maintained in 50%/, fair con- hypertensive therapy and it is in this group that trol (diastolic blood pressure less than 110 mmHg) in complications of hypertension are most likely to 35%/ and poor control (diastolic blood pressure more develop. The incidence of complications developing than 110 mmHg) in only 15%. In all fifty-six of the whilst on thiazides alone is shown in Table 4. 227 cases (20 2%) eventually required the addition of At the start of treatment thirty-four patients had a more potent agent, and the time when this became a raised blood urea, but the majority did not show a rise. Six patients developed significant renal necessary is shown in Fig. 5. http://pmj.bmj.com/ failure, but all had underlying renal disease. 200 Hypokalaemia There was a marked fall in the plasma potassium in most cases as shown in Fig. 3 which compares the 180 _ pre-treatment plasma potassium with the average of TABLE 4. Complications of hyper- X 160 on October 2, 2021 by guest. E_ tension developing whilst on treat- ment with thiazides ma- 140- No. of patients 0 Cardiac infarct 15 E12 Before Angina 32 treatment Cardiac failure 9 I00 Stroke 10 On Renal failure 5 thiazides Blood urea at end of study FIG. 2. Pre-treatment and treatment mean systolic and 40-60 mg/100 ml 44 diastolic blood pressures. Over 60 mg/I00 ml 10 641 Treatment of hypertension with diuretics Postgrad Med J: first published as 10.1136/pgmj.47.552.639 on 1 October 1971. Downloaded from 40 (a) 50 30 20 40 n~~~~~~~~~~10 7 30 e 0 40 20 @120 X:A~~~~~~~/ 0 Protected by copyright. 2-0-2 42-5-2-9 3-0-3-43-5-3-94-0-4-44-5-4-95-0-5.4 '5-5 15-19 20-24 25-29 30-34 35-39 Serum pot4ssium (mEq/ ) Plasma total C02 (mEq/L) FIG. 3. (a) Serum potassium pre-treatment (143 patients). Mean, 4 30; SD, 0-61. (b) Serum potassium on treat- FIG. 4. Final plasma total CO2 on treatment (157 ment (180 patients). Mean, 3 S4; SD, 0-47. patients). the plasmia potassium on treatment. Patients who Hyperuricaemia and gout developed a very low plasma potassium were given Four patients (1 7%) developed clinical gout with increasing doses of potassium supplement. How- hyperuricaemia and one other developed an arthro- ever, no cases at any time developed subjective to Some pathy with a normal serum uric acid. Those patients symptomLs attributable hypokalaemia. with gout were effectively treated with allopruinol or patients developed suspicious symptoms, but these probenecid. patients had their uric were the dose of Ninety-six serum not altered by increasing potassium acid estimated and eighteen of these were greater supplements and elevating the plasma potassium. than 7 0 mg/100 ml giving an incidence of hyper- uricaemia of 18% of estimations. Metabolic alkalosis http://pmj.bmj.com/ During the period of observation there was a In no cases was it necessary to discontinue therapy change in the method of estimation, and laboratory on account of side-effects of thiazide diuretics. normals, of the plasma total C02 so only the most recent value is submitted-otherwise the com- Discussion parison would not be real. However, Fig. 4 demon- In the majority of the 227 patients who were strates that analkalosis developed in a largenumber of maintained on thiazide diuretics for up to 12 years, cases: the present normal level for this laboratory is it was possible to achieve good control of the blood 24-32mEq/1. The plasma total CO2 was over 30 mEq/1 pressure with no symptoms attributable to the on October 2, 2021 by guest. in ninety-six out of 157 patients examined (62%). administration of the drugs except a low incidence of diabetes and gout. The patients in this report all had Carbohydrate intolerance a severe manometric hypertension with mean pre- Two patients had hyperglycaermia and glycosuria treatment levels of blood pressure of 203-4 mmHg before starting thiazides and there wvas one case of systolic and 1206 mmHg diastolic, and many had renal glycosuria. After starting thiazides the two either symptoms or objective complications of raised hyperglycaemic patients did not require hypogly- arterial pressure (Table 2). In spite of this the caenmic agents, but were controlled by diet alone. majority were adequately controlled, without re- Five other patients (2 2%) developed hyperglycaemia course to more potent anti-hypertensive agents. The after starting thiazides-of which three required incidence of complications of hypertension whilst on antidiabetic drugs. treatment is low (Table 4), although this is partly 642 D. G. Beevers, M. Hamilton and J. E. Harpur Postgrad Med J: first published as 10.1136/pgmj.47.552.639 on 1 October 1971.
Recommended publications
  • Association of Hypertensive Status and Its Drug Treatment with Lipid and Haemostatic Factors in Middle-Aged Men: the PRIME Study
    Journal of Human Hypertension (2000) 14, 511–518 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study P Marques-Vidal1, M Montaye2, B Haas3, A Bingham4, A Evans5, I Juhan-Vague6, J Ferrie`res1, G Luc2, P Amouyel2, D Arveiler3, D McMaster5, JB Ruidavets1, J-M Bard2, PY Scarabin4 and P Ducimetie`re4 1INSERM U518, Faculte´ de Me´decine Purpan, Toulouse, France; 2MONICA-Lille, Institut Pasteur de Lille, Lille, France; 3MONICA-Strasbourg, Laboratoire d’Epide´miologie et de Sante´ Publique, Strasbourg, France; 4INSERM U258, Hoˆ pital Broussais, Paris, France; 5Belfast-MONICA, Department of Epidemiology, The Queen’s University of Belfast, UK; 6Laboratory of Haematology, La Timone Hospital, Marseille, France Aims: To assess the association of hypertensive status this effect remained after multivariate adjustment. Cal- and antihypertensive drug treatment with lipid and hae- cium channel blockers decreased total cholesterol and mostatic levels in middle-aged men. apoproteins A-I and B; those differences remained sig- Methods and results: Hypertensive status, antihyperten- nificant after multivariate adjustment. ACE inhibitors sive drug treatment, total and high-density lipoprotein decreased total cholesterol, triglycerides, apoprotein B (HDL) cholesterol, triglyceride, apoproteins A-I and B, and LpE:B; and this effect remained after multivariate lipoparticles LpA-I,
    [Show full text]
  • The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression
    BASIC RESEARCH www.jasn.org The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression Masayoshi Nanami,1 Truyen D. Pham,1 Young Hee Kim,1 Baoli Yang,2 Roy L. Sutliff,3 Olivier Staub,4,5 Janet D. Klein,1 Karen I. Lopez-Cayuqueo,6,7 Regine Chambrey,8 Annie Y. Park,1 Xiaonan Wang,1 Vladimir Pech,1 Jill W. Verlander,9 and Susan M. Wall1,10 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Nedd4–2 is an E3 ubiquitin-protein ligase that associates with transport proteins, causing their ubiquitylation, and then internalization and degradation. Previous research has suggested a corre- lation between Nedd4–2 and BP. In this study, we explored the effect of intercalated cell (IC) Nedd4–2 gene ablation on IC transporter abundance and function and on BP. Methods We generated IC Nedd4–2 knockout mice using Cre-lox technology and produced global pen- 2/2 drin/Nedd4–2 null mice by breeding global Nedd4–2 null (Nedd4–2 ) mice with global pendrin null 2/2 (Slc26a4 ) mice. Mice ate a diet with 1%–4% NaCl; BP was measured by tail cuff and radiotelemetry. We 2 measured transepithelial transport of Cl and total CO2 and transepithelial voltage in cortical collecting ducts perfused in vitro. Transporter abundance was detected with immunoblots, immunohistochemistry, and immunogold cytochemistry. 2 2 Results IC Nedd4–2 gene ablation markedly increased electroneutral Cl /HCO3 exchange in the cortical col- lecting duct, although benzamil-, thiazide-, and bafilomycin-sensitive ion flux changed very little.
    [Show full text]
  • Comparing the Efficacy of Angiotensin Converting Enzyme In- Hibitors with Calcium Channel Blockers on the Treatment of Di- Abetic Nephropathy: a Meta-Analysis
    Iran J Public Health, Vol. 48, No.2, Feb 2019, pp.189-197 Review Article Comparing the Efficacy of Angiotensin Converting Enzyme In- hibitors with Calcium Channel Blockers on the Treatment of Di- abetic Nephropathy: A Meta-Analysis *Zhaowei ZHANG 1, Chunlin CHEN 2, Shiwen LV 1, Yalan ZHU 1, Tianzi FANG 1 1. Department of Pharmacy, Jin Hua Municipal Central Hospital, Jin Hua 32100, China 2. College of Chemistry and Bio-Engineering, Yi Chun University, Yi Chun 336000, China *Corresponding Author: Email: [email protected] (Received 21 Mar 2018; accepted 11 Jun 2018) Abstract Background: The angiotensin-converting enzyme inhibitors (ACEIs) could improve the symptoms of diabetic nephropathy. Whether the calcium channel blockers (CCBs) could be as effective as ACEIs on treating diabetic nephropathy is controversial. Here, we aimed to compare the efficacy of ACEIs with CCBs on the treatment of diabetic nephropathy by performing a meta-analysis of randomized controlled trials (RCTs). Methods: The Pubmed, Medline, Embase and The Cochrane Database were searched up to July 2017 for eli- gible randomized clinical trials studies. Effect sizes were summarized as mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (P-value<0.05). Results: Seven RCTs involving 430 participants comparing ACEIs with CCBs were included. No benefit was seen in comparative group of ACEIs on systolic blood pressure(SBP) (MD=1.05 mmHg; 95% CI: -0.97 to 3.08, P=0.31), diastolic blood pressure (DBP) (MD= -0.34 mmHg; 95% CI: -1.2 to 0.51, P=0.43), urinary al- bumin excretion rates (UAER) (MD=1.91μg/min; 95% CI: -10.3 to 14.12, P=0.76), 24-h urine protein (24-UP) (SMD=-0.26; 95%CI: -0.55 to 0.03, P=0.08), glomerular filtration rate (GFR) (SMD=0.01; 95% CI: -0.38 to 0.41, P=0.95).
    [Show full text]
  • Actual Place of Diuretics in Hypertension Treatment
    Mini Review J Cardiol & Cardiovasc Ther Volume 3 Issue 4 - March 2017 Copyright © All rights are reserved by Farouk Abcha DOI: 10.19080/JOCCT.2017.03.555616 Actual Place of Diuretics in Hypertension Treatment Farouk Abcha, Marouane Boukhris*, Zied Ibn Elhadj, Lobna Laroussi, Faouzi Addad, Afef Ben Halima and Salem Kachboura Cardiology Department of Abderrahmen Mami Hospital, University of Tunis El Manar, Tunisia Submission: February 03, 2017; Published: March 07, 2017 *Corresponding author: Marouane Boukhris, Cardiology Department of Abderrahmen Mami Hospital, Ariana, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia, Tel: ; Email: Abstract Diuretics represent a large and heterogeneous class of drugs, differing from each other by structure, site and mechanism of action. Diuretics are widely used, and have several indications in different cardiovascular disorders, particularly in hypertension and heart failure. Despite the large number of available anti-hypertensive drugs, diuretics remained a cornerstone of hypertension treatment. In the current editorial, we assessed the actual place of different diuretics in the hypertension guidelines focusing on the concept of tailored approach in prescribing them for hypertensive patients. Keywords: Diuretics; Hypertension; Hydrochlorothiazide; Indapamide; Guidelines Introduction Diuretics represent a large and heterogeneous class of drugs, differing from each other by structure, site and mechanism of action. Diuretics are widely used, and have several indications in different cardiovascular disorders, particularly in hypertension and heart failure. Despite the large number of available anti-hypertensive drugs, diuretics remained a cornerstone of hypertension treatment [1]. Indeed, they are the second most commonly prescribed class of antihypertensive medication. For instance, 12% of US adults were prescribed a diuretic, and the relative increase in prescriptions from 1999 through 2012 was 1.4 [2].
    [Show full text]
  • The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression
    BASIC RESEARCH www.jasn.org The Role of Intercalated Cell Nedd4–2 in BP Regulation, Ion Transport, and Transporter Expression Masayoshi Nanami,1 Truyen D. Pham,1 Young Hee Kim,1 Baoli Yang,2 Roy L. Sutliff,3 Olivier Staub,4,5 Janet D. Klein,1 Karen I. Lopez-Cayuqueo,6,7 Regine Chambrey,8 Annie Y. Park,1 Xiaonan Wang,1 Vladimir Pech,1 Jill W. Verlander,9 and Susan M. Wall1,10 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Nedd4–2 is an E3 ubiquitin-protein ligase that associates with transport proteins, causing their ubiquitylation, and then internalization and degradation. Previous research has suggested a corre- lation between Nedd4–2 and BP. In this study, we explored the effect of intercalated cell (IC) Nedd4–2 gene ablation on IC transporter abundance and function and on BP. Methods We generated IC Nedd4–2 knockout mice using Cre-lox technology and produced global pen- 2/2 drin/Nedd4–2 null mice by breeding global Nedd4–2 null (Nedd4–2 ) mice with global pendrin null 2/2 (Slc26a4 ) mice. Mice ate a diet with 1%–4% NaCl; BP was measured by tail cuff and radiotelemetry. We 2 measured transepithelial transport of Cl and total CO2 and transepithelial voltage in cortical collecting ducts perfused in vitro. Transporter abundance was detected with immunoblots, immunohistochemistry, and immunogold cytochemistry. 2 2 Results IC Nedd4–2 gene ablation markedly increased electroneutral Cl /HCO3 exchange in the cortical col- lecting duct, although benzamil-, thiazide-, and bafilomycin-sensitive ion flux changed very little.
    [Show full text]
  • Initial Medication Selection for Treatment of Hypertension in an Open-Panel HMO
    J Am Board Fam Pract: first published as 10.3122/jabfm.8.1.1 on 1 January 1995. Downloaded from Initial Medication Selection For Treatment Of Hypertension In An Open-Panel HMO Micky jerome, PharmD, MBA, George C. Xakellis, MD, Greg Angstman, MD, and Wayne Patchin, MBA Background: During the past 25 years recommendations for treating hypertension have evolved from a stepped-care approach to monotherapy or sequential monotherapy as experience has been gained and new antihypertensive agents have been introduced. In an effort to develop a disease management strategy for hypertension, we investigated the prescribing patterns of initial medication therapy for newly treated hypertensive patients. Methods: We examined paid claims data of an open-panel HMO located in the midwest. Charts from 377 patients with newly treated hypertension from a group of 12,242 hypertenSive patients in a health insurance population of 85,066 persons were studied. The type of medication regimen received by patients newly treated for hypertension during an 18-month period was categorized into monotherapy, sequential monotherapy, stepped care, and initial treatment with multiple agents. With monotherapy, the class of medication was also reported. Associations between use of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, or (3-blockers and presence of comorbid conditions were reported. Results: Fifty-five percent of patients received monotherapy, 22 percent received stepped care, and 18 percent received sequential monotherapy. Of those 208 patients receiving monotherapy, 30 percent were prescribed a calcium channel blocker, 22 percent an ACE inhibitor, and 14 percent a f3-blocker. No customization of treatment for comorbid conditions was noted.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • RESEARCH UPDATES (Cont.)
    RESEARCH UPDATES (cont.) RESEARCH UPDATES Resident Editors: David Bunch, Pharm.D., Ally Kingsbury, Pharm.D., Monika Tawfik, Pharm.D. Faculty Editors: Sarah Schweiss, Pharm.D., BCACP RESEARCH UPDATES Volume 18, Issue 1 – First The HUNT Study: Proton Pump Inhibitors and Fracture Risk1 Quarter 2020 Kaylin Maddy, PharmD Park Nicollet Health Services Research Updates The HUNT Study: Proton Pump Background: Proton pump inhibitors (PPIs) are broadly prescribed for gastrointestinal conditions. These medications have been correlated with an increased risk of fractures Inhibitors and Fracture Risk in multiple previous studies, however a definite causative link is not well understood. A Comparison of Two LDL The FDA requires PPI packaging information to include a warning about increased hip, Cholesterol Targets after Ischemic wrist, or spine fracture risk with long term and high dose PPI use. Many mechanisms for this risk have been proposed including reduced calcium and magnesium absorption, Stroke though these have not been adequately demonstrated in humans. Therapeutic Thoughts Purpose: The Nord-Trøndelag Health Study (HUNT) study aimed to examine a possible Migraine Pharmacotherapy and association between the use of PPIs and risk of fracture in a large group of Norwegian individuals. Novel Agents Study Design: A total of 15,017 women and 13,241 men aged 50 to 85, with a mean age Antihypertensive Treatment of 65 years old were analyzed. Data was retrospectively reviewed from a large Update Norwegian Health Study (HUNT3), the Norwegian Fracture Registry, and the Norwegian Prescription Database. The fracture registry collects information on hip and Who Should Receive PCV13? forearm fractures. History of exposure to PPIs, anti-osteoporotic drugs (AODs), and oral glucocorticoids (GCs) were pulled from the prescription database.
    [Show full text]
  • Pharmacy Précis
    Samford University Global Drug Information Service PHARMACY RÉCIS P Précis: a concise summary of essential points, statements or facts Volume 30 (Issue 1) January 2012 NEW MOLECULAR ENTITIES OF 2011 New molecular entities, biologic agents, and drug formulations/combinations approved during 2011 (including indication, approval date, and comments) are presented in this issue of Pharmacy Précis. An explanation of the FDA classification of the new drugs also is included. If you need any additional information regarding these agents, please call the Samford University Global Drug Information Service at (205) 726-2659. FDA classifications for newly approved drugs are based on chemical classification and are outlined below. FDA CLASSIFICATIONS CHEMICAL CLASSIFICATION THERAPEUTIC CLASSIFICATION 1. New molecular entity - drug S = Standard review - assigned not marketed in U.S. by any to drugs that appear to have manufacturer therapeutic qualities similar to 2. New salt - active moiety is drugs already approved marketed in the U.S., but this P = Priority review - assigned particular salt, ester, or to drugs that appear to have derivative is not therapeutic gain over drugs 3. New formulation - drug currently available marketed in the U.S., but this O = Orphan designation - particular formulation is not Pursuant to Section 526 of the 4. New combination - two or Orphan Drug Act (Public Law more ingredients in 97-414 as amended). combination not marketed in 1. Providing effective therapy the U.S. or diagnosis for a disease 5. New manufacturer - already not adequately treated or marketed by another firm; diagnosed by any marketed duplicated salt, formulation or drug combination 2. Providing improved 6.
    [Show full text]
  • Self-Measured Compared to Office
    Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Supplemental Tables and Figures Part 1: Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension Table 1.1 Electronic search terms used for the current meta-analysis (Part 1 – Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension). PubMed Search (Blood Pressure Monitoring, Ambulatory [mesh] OR self care [mesh] OR telemedicine [mesh] OR patient participation [tiab] OR ambulatory [tiab] OR kiosk [tiab] OR kiosks [tiab] OR self-monitor* [tiab] OR self-measure* [tiab] OR self-care* [tiab] OR self-report* [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR home monitor* [tiab] OR telehealth [tiab] OR tele-health [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR telemedicine [tiab] OR patient-directed [tiab] OR Blood pressure monitoring “patient directed” [tiab] OR HMBP [tiab] OR SMBP [tiab] OR home [tiab] OR white coat [tiab] OR concept + Self Care concept ((patient participation [ot] OR ambulatory [ot] OR kiosk [ot] OR kiosks [ot] OR self-monitor* [ot] OR self-measure* [ot] OR self-care* [ot] OR self-report* [ot] OR telemonitor* [ot] OR tele-monitor* [ot] OR home monitor* [ot] OR telehealth [ot] OR tele-health [ot] OR telemonitor* [ot] OR tele- monitor* [ot] OR telemedicine [ot] OR patient-directed [tiab] OR “patient directed” [tiab]
    [Show full text]
  • Australian Public Assessment Report for Aliskiren, Amlodipine and Hydrochlorothiazide Proprietary Product Name: Rasilamlo HCT
    Australian Public Assessment Report for Aliskiren, Amlodipine and Hydrochlorothiazide Proprietary Product Name: Rasilamlo HCT Sponsor: Novartis Pharmaceuticals Australia Pty Ltd June 2012 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is a division of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. · TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website. About AusPARs · An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. · An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Systematic Evidence Review from the Blood Pressure Expert Panel, 2013
    Managing Blood Pressure in Adults Systematic Evidence Review From the Blood Pressure Expert Panel, 2013 Contents Foreword ............................................................................................................................................ vi Blood Pressure Expert Panel ..............................................................................................................vii Section 1: Background and Description of the NHLBI Cardiovascular Risk Reduction Project ............ 1 A. Background .............................................................................................................................. 1 Section 2: Process and Methods Overview ......................................................................................... 3 A. Evidence-Based Approach ....................................................................................................... 3 i. Overview of the Evidence-Based Methodology ................................................................. 3 ii. System for Grading the Body of Evidence ......................................................................... 4 iii. Peer-Review Process ....................................................................................................... 5 B. Critical Question–Based Approach ........................................................................................... 5 i. How the Questions Were Selected ................................................................................... 5 ii. Rationale for the Questions
    [Show full text]